Axitinib

CAS No. 319460-85-0

Axitinib( AG-013736 )

Catalog No. M14039 CAS No. 319460-85-0

Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 46 In Stock
25MG 31 In Stock
50MG 42 In Stock
100MG 57 In Stock
200MG 72 In Stock
500MG 140 In Stock
1G 203 In Stock

Biological Information

  • Product Name
    Axitinib
  • Note
    Research use only, not for human use.
  • Brief Description
    Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3.
  • Description
    Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    AG-013736
  • Pathway
    Angiogenesis
  • Target
    PDGFR
  • Recptor
    PDGFRβ| VEGFR1/FLT1| VEGFR2/Flk1| VEGFR2/KDR| VEGFR3
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    319460-85-0
  • Formula Weight
    386.47
  • Molecular Formula
    C22H18N4OS
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 35 mg/mL warmed (90.56 mM)
  • SMILES
    O=C(NC)C1=CC=CC=C1SC2=CC3=C(C=C2)C(/C=C/C4=NC=CC=C4)=NN3
  • Chemical Name
    (E)-N-methyl-2-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)benzamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Hu-Lowe DD, et al. Clin Y Res, 2008, 14(22), 7272-7283.
molnova catalog
related products
  • Regorafénib N-oxyde ...

    Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, RET, Kit, and Raf-1.

  • PP58

    PP58 is an inhibit of PDGFR, FGFR and Src family.

  • Toceranib

    Toceranib phosphate is an orally active inhibitor of tyrosine kinase (RTK) receptor, and it potently inhibits PDGFR, VEGFR, and Kit(with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively), has antitumor and antiangiogenic activity.